



ORIGINAL ARTICLE

## Diagnostic yield of current referral strategies for elective coronary angiography in suspected coronary artery disease—An analysis of the ACROSS registry

Miguel Borges Santos\*, António Miguel Ferreira, Pedro de Araújo Gonçalves, Luís Raposo, Rui Campante Teles, Manuel Almeida, Miguel Mendes

Departamento de Cardiologia, Hospital de Santa Cruz, Lisboa, Portugal

Received 5 September 2012; accepted 1 November 2012

Available online 7 June 2013

### KEYWORDS

Coronary angiography;  
Chest pain/diagnosis;  
Stable angina;  
Myocardial ischemia

### Abstract

**Introduction and Objectives:** The purpose of this study was to assess the diagnostic yield of current referral strategies for elective invasive coronary angiography (ICA).

**Methods:** We performed a cross-sectional observational study of consecutive patients without known coronary artery disease (CAD) undergoing elective ICA due to chest pain symptoms. The proportion of patients with obstructive CAD (defined as the presence of at least one  $\geq 50\%$  stenosis on ICA) was determined according to the use of noninvasive testing.

**Results:** The study population consisted of 1892 individuals (60% male, mean age  $64 \pm 11$  years), of whom 1548 (82%) had a positive noninvasive test: exercise stress test (41%), stress myocardial perfusion imaging (36%), stress echocardiogram (3%) or coronary computed tomography angiography (3%). Referral without testing occurred in 18% of patients. The overall prevalence of obstructive CAD was 57%, higher among those with previous testing (58% vs. 51% without previous testing,  $p=0.026$ ) and when anatomic rather than functional tests were used (81.3% vs. 57.1%,  $p=0.001$ ). A positive test and conventional risk factors were all independent predictors of obstructive CAD, with adjusted odds ratios (95% confidence interval) of 1.34 (1.03–1.74) for non-invasive testing, 1.05 (1.04–1.06) for age, 3.48 (2.81–4.29) for male gender, 1.86 (1.32–2.62) for current smoking, 1.74 (1.38–2.20) for diabetes, 1.30 (1.04–1.62) for hypercholesterolemia, and 1.39 (1.08–1.80) for hypertension.

**Conclusions:** More than 40% of patients without known CAD undergoing elective ICA did not have obstructive lesions, even though four out of five had a positive noninvasive test. These exams were relatively weak gatekeepers; functional tests were more often used but appeared to be outperformed by the anatomic test.

© 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved.

\* Corresponding author.

E-mail address: [c.miguel.santos@gmail.com](mailto:c.miguel.santos@gmail.com) (M. Borges Santos).

**PALAVRAS-CHAVE**

Angiografia coronária;  
Dor  
torácica/diagnóstico;  
Angina estável;  
Isquemia miocárdica

## Rendimento das atuais estratégias de referência para coronariografia eletiva por suspeita de doença coronária—análise do registo ACROSS

**Resumo**

**Introdução e objetivos:** O objetivo do estudo foi avaliar o rendimento das atuais estratégias de referência eletiva para coronariografia invasiva.

**Métodos:** Estudo transversal de indivíduos consecutivos sem doença coronária conhecida submetidos a coronariografia por dor torácica. Determinação da prevalência de doença coronária obstrutiva (definida pela presença de pelo menos uma estenose  $\geq 50\%$ ) de acordo com a utilização de testes não-invasivos para despiste de cardiopatia isquémica.

**Resultados:** Foram avaliados 1892 indivíduos (60% homens, idade média  $64 \pm 11$  anos), dos quais 1548 (82%) tinham um teste não-invasivo positivo: prova de esforço (41%), cintigrafia de perfusão miocárdica (36%), ecocardiograma de *stress* (3%) e angiografia coronária por tomografia computadorizada (3%). Ocorreu referência sem teste prévio em 18% dos doentes. A prevalência global de doença obstrutiva foi 57%, sendo mais elevada nos doentes submetidos a testes não-invasivos (58% *versus* 51% nos doentes sem testes prévios,  $p = 0,026$ ) e naqueles em que o teste era anatómico *versus* funcional (81,3% *versus* 57,1%,  $p = 0,001$ ). Um teste não-invasivo positivo e fatores de risco convencionais foram preditores independentes de doença obstrutiva, com *odds-ratio* ajustado (intervalo confiança 95%) de: teste não-invasivo 1,34 (1,03-1,74), idade 1,05 (1,04-1,06), sexo masculino 3,48 (2,81-4,29), tabagismo ativo 1,86 (1,32-2,62), diabetes 1,74 (1,38-2,20), hipercolesterolemia 1,30 (1,04-1,62) e hipertensão 1,39 (1,08-1,80).

**Conclusões:** Mais de 40% dos doentes sem doença coronária conhecida que realizam coronariografia eletiva não têm doença obstrutiva, apesar de quatro em cada cinco ter um teste não-invasivo positivo. Estes testes são *gatekeepers* relativamente fracos; os funcionais foram utilizados mais frequentemente mas o anatómico pareceu ter melhor desempenho.

© 2012 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L. Todos os direitos reservados.

**List of abbreviations**

CAD	coronary artery disease
CCTA	coronary computed tomography angiography
ECG	electrocardiogram
ICA	invasive coronary angiography
SPECT	single-photon emission computed tomography


**Introduction**

The evaluation of patients with suspected coronary artery disease (CAD) is based on clinical assessment, often supplemented by noninvasive tests which serve as gatekeepers for invasive coronary angiography (ICA).<sup>1-3</sup> ICA is the diagnostic gold standard for CAD but is costly, has limited availability and carries a risk of complications related to its invasive nature.<sup>4</sup> The aims of performing noninvasive testing in this setting include minimizing unnecessary risks and costs, and identifying patients who will benefit from revascularization. However, despite the frequent use of noninvasive testing, a significant proportion of patients undergoing ICA do not have obstructive CAD or are not eligible for revascularization.<sup>5,6</sup> The purpose of this study was to assess current patterns of noninvasive testing and to appraise their diagnostic yield among symptomatic patients undergoing ICA for suspected CAD.

**Methods****Population**

This was an observational, cross-sectional study performed at a single hospital center serving an urban population of 900 000 inhabitants in Lisbon, Portugal. The study population consisted of all patients referred for elective ICA for evaluation of chest pain symptoms between January 2006 and November 2010. Patients' referral for ICA and the decision to perform previous noninvasive testing, including the testing modality, were left to the discretion of attending physicians. Noninvasive testing was performed mostly at private practice facilities.

The modalities of noninvasive testing were exercise electrocardiogram (ECG) stress testing, stress myocardial single-photon emission computed tomography (SPECT), stress echocardiography and coronary computed tomography angiography (CCTA). 'Ischemic changes' on the resting ECG were not considered noninvasive testing. The following exclusion criteria were applied sequentially: non-elective setting (acute coronary syndrome), previously known CAD (defined as previous acute coronary syndrome, revascularization procedure or documented coronary stenosis  $\geq 50\%$  on previous ICA), preoperative evaluation, presenting symptom other than chest pain, negative noninvasive test result and incomplete information on patients' clinical characteristics or ICA result.



**Figure 1** Selection of the study population. ACS: acute coronary syndrome; CAD: coronary artery disease; preop: preoperative.

### Patient evaluation

Data on demographic characteristics, cardiovascular risk factors, type of noninvasive testing and results of coronary angiography were prospectively collected in the ongoing ACROSS (Angiography and Coronary Revascularization On Santa Cruz Hospital) registry, approved by the local ethics committee. The diagnoses of hypertension, hypercholesterolemia and diabetes (regardless of type, duration or current treatment) were assigned if indicated in the patients' referral letter or if the patient was being treated with anti-hypertensive or lipid-lowering drugs, oral antidiabetics or insulin. To avoid underdiagnosis, obstructive coronary was defined as a  $\geq 50\%$  reduction in vessel diameter as compared to a nondiseased proximal segment. This broad definition of obstructive CAD was not used as a criterion for revascularization.

### Statistical analysis

Data are presented as counts (%), medians (interquartile range) or means  $\pm$  standard deviation. Categorical variables were compared using Fisher's exact test. Continuous variables were compared by means of the t test. Patients with and without obstructive CAD were compared for differences in age, gender, body mass index, prevalence of cardiovascular risk factors and use of noninvasive testing. Variables that showed significant association with obstructive CAD ( $p < 0.10$ ) in univariate analysis were included in a binary logistic regression model to identify independent predictors. Temporal differences during the study period in the prevalence of obstructive CAD and the use of noninvasive

testing were assessed using the chi-square test for trend. A two-sided p-value of less than 0.05 was considered to indicate statistical significance. All analyses were performed using the statistical package SPSS<sup>®</sup> version 17.0 (SPSS, Inc., Chicago, IL).

### Results

During the study period, 11 523 patients underwent ICA at our hospital. After the exclusion criteria were applied (Figure 1), 1892 patients were included in the analysis.

Most patients (81.8%,  $n=1548$ ) were referred after a positive noninvasive test. On ICA, the overall prevalence of obstructive CAD was 56.7% (1072/1892). One-vessel, two-vessel or three-vessel/left main disease were identified in 21.1% ( $n=398$ ), 17.1% ( $n=323$ ) and 18.6% ( $n=351$ ) of patients, respectively. The prevalence of obstructive CAD was lower in patients referred without previous noninvasive testing than in those with a positive test (51.2% vs. 57.9%,  $p=0.026$ ). Myocardial revascularization (percutaneous coronary intervention or referral for coronary artery bypass grafting) was performed in 46.7% ( $n=883$ ) of patients.

Increasing age, male gender, traditional cardiovascular risk factors and positive noninvasive testing were predictors of obstructive CAD in univariate and multivariate analysis (Table 1).

There were no significant temporal differences in the prevalence of obstructive CAD during the study period, despite a significant increase in the proportion of patients undergoing noninvasive testing (Figure 2). Exercise stress testing and stress SPECT were the most used tests,

**Table 1** Population characteristics.

	Total	Univariate analysis			Multivariate analysis		
		Obstructive CAD (n=1072)	No obstructive CAD (n=820)	p	Adjusted odds ratio	95% CI	p
Age, years	64±11	65.7±10.4	61.7±11.0	<0.001	1.05	1.04–1.06	<0.001
Male, n (%)	1141 (60.3%)	769 (71.7%)	372 (45.4%)	<0.001	3.48	2.81–4.29	<0.001
Body mass index, kg/m <sup>2</sup>	28.0±3.9	27.6±3.9	28.0±4.5	0.030	0.98	0.96–1.01	0.240
<b>Cardiovascular risk factors, %</b>							
Hypertension	78.4%	81.3%	74.6%	<0.001	1.39	1.08–1.80	0.011
Diabetes	27.5%	32.5%	21.1%	<0.001	1.74	1.38–2.20	<0.001
Smoking	11.4%	13.2%	8.9%	0.003	1.86	1.32–2.62	<0.001
Hypercholesterolemia	69.2%	71.9%	65.7%	0.004	1.30	1.04–1.62	0.019
Previous positive noninvasive testing	81.8%	83.6%	79.5%	0.026	1.34	1.03–1.74	0.028

CAD: coronary artery disease; CI: confidence interval.


accounting for more than 90% of noninvasive testing. CCTA use increased significantly from 2006 to 2010.

The rates of obstructive coronary artery disease and myocardial revascularization according to type of noninvasive testing are presented in Figure 3. Comparing functional and anatomic tests, the prevalence of obstructive CAD (57.1% vs. 81.3%, p=0.001) was higher in the latter group.


**Discussion**

**Diagnostic yield of the current referral strategy**

In our European, urban clinical setting, less than 57% of patients referred for elective ICA for evaluation of chest pain symptoms had obstructive lesions (defined by a broad criterion of ≥50% luminal stenosis), despite the fact that four out of five patients had undergone previous testing. Noninvasive testing was frequently used but was only a weak independent predictor of obstructive CAD (OR 1.34, p=0.028). This apparently low performance of noninvasive



**Figure 3** Rate of obstructive coronary artery disease and myocardial revascularization according to type of noninvasive testing. CAD: coronary artery disease; CTA: computed tomography angiography; ECG: electrocardiogram; Echo: echocardiogram; SPECT: single-photon emission computed tomography.



**Figure 2** Trends of noninvasive testing between 2006 and 2010. CAD: coronary artery disease; CTA: computed tomography angiography; ECG: electrocardiogram; Echo: echocardiogram; SPECT: single-photon emission computed tomography.

tests as gatekeepers for ICA has several possible explanations. One is that the performance of these tests in the "real world" is worse than that reported in the literature from large experienced centers. Another explanation would be a low pretest probability of obstructive CAD in this population, resulting in a relatively large absolute number of patients without obstructive disease undergoing ICA.<sup>7</sup> A third hypothesis, supported by increasing evidence,<sup>6,8</sup> is that the pretest likelihood of angiographically significant CAD may be overestimated when calculated on the basis of age, gender and chest pain characteristics in accordance with the seminal work of Diamond, Forrester and Pryor.<sup>9,10</sup>

The yield of any diagnostic test depends on the pretest likelihood of the patients in whom it is used and on the way the test modifies that probability. Ideally, a positive noninvasive test should increase the probability of obstructive disease to a level that justifies performing ICA, and a negative test should reduce that likelihood to a level at which obstructive CAD can be safely ruled out. While ICA will always be performed on some patients without coronary lesions, the 2011 standards for catheterization laboratory accreditation from the Accreditation for Cardiovascular Excellence organization suggest that the incidence of non-obstructive disease in elective patients should be <40%. In the interests of individual patients and of overall healthcare cost-effectiveness, extreme rates are undesirable. Recently, Genders et al.<sup>6</sup> reported a rate of obstructive CAD of 58% (ranging from 39.4% to 75.5%) in a multicenter study involving 11 European hospitals. In the USA, Patel et al.<sup>5</sup> reported an overall rate of 41% of patients with obstructive CAD in the National Cardiovascular Data Registry, although this varied significantly between different centers, from 23 to 100%.<sup>11</sup> Taken together, these studies suggest that better gatekeepers are needed. Our findings are in line with both these studies, underlining the relatively low prevalence of obstructive CAD on ICA in a population with a high frequency of noninvasive testing.

We were also able to assess differences between noninvasive tests. It should be noted that our findings are mainly the result of using functional tests, particularly exercise ECG and stress SPECT, which accounted for more than 90% of testing, as gatekeepers for ICA. Although the proportion of obstructive CAD was higher in the CCTA group than for functional tests, it is uncertain whether the overall results would have been different if anatomic tests had been used more frequently. There is some evidence that CCTA may be a useful and cost-effective gatekeeper for ICA (particularly in patients with intermediate to low pretest probability), reducing the number of patients without obstructive CAD referred for invasive testing.<sup>12-19</sup> Recent guidelines for the management of patients with chest pain from the United Kingdom's National Institute for Health and Clinical Excellence (NICE) recommend choosing tests according to the pretest probability of CAD. Functional imaging tests are preferred for patients with 30-60% pretest probability of disease, whereas CCTA (preceded by calcium score) is the preferred method for patients with 10-29% pretest probability.<sup>20</sup> According to these guidelines, ICA should be offered as the first test to patients with pretest probabilities over 60%. Currently, there is disagreement over which type of test should be used as first line.<sup>21</sup> Results from the US

National Institutes of Health-sponsored PROMISE study (a clinical endpoint-driven randomized study comparing functional studies with CCTA for the evaluation of patients with suspected CAD) will hopefully shed more light on this matter.<sup>22,23</sup>

### Study limitations

Several limitations of this study should be acknowledged. Since the characteristics of chest pain were not systematically assessed and recorded for each patient, it was not possible to calculate the pretest probability of CAD. Although the median age and prevalence of risk factors are compatible with a typical CAD risk population, it is not possible to ascertain whether the weak predictive power of noninvasive testing is related to its application to a population with low pretest probability. Another pitfall is related to the dichotomized classification of noninvasive tests as positive or negative for obstructive CAD. In most tests there is a continuum of 'positivity' which is difficult to address with this study design. It should also be emphasized that this was not a randomized trial of noninvasive testing and, as such, direct comparisons of testing vs. no testing and comparisons between noninvasive modalities should be interpreted with caution. The diagnostic performance of noninvasive testing is dependent on the pretest probability of disease, and the decision to perform noninvasive testing and the choice of the test itself depend on the physician's perception of pretest probability, which may have differed between the different diagnostic modalities applied.

### Conclusions

Nearly half of patients without known CAD undergoing elective ICA due to chest pain did not have obstructive lesions, even though four out of five had a positive noninvasive test. Functional tests were by far the most commonly used gatekeepers but were relatively weak predictors of obstructive CAD and appear to be outperformed by CCTA. There is considerable room for improving the current referral strategy for ICA.

### Ethical disclosures

**Protection of human and animal subjects.** The authors declare that no experiments were performed on humans or animals for this study.

**Confidentiality of data.** The authors declare that they have followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in the study.

**Right to privacy and informed consent.** The authors declare that no patient data appear in this article.

### Conflicts of interest

The authors have no conflicts of interest to declare.



## References

1. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). *Circulation*. 2003;107:149–58.
2. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. *Eur Heart J*. 2006;27:1341–81.
3. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. *Eur Heart J*. 2010;31:2501–55.
4. Bashore TM, Bates ER, Berger PB, et al. American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2001;37:2170–214.
5. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. *N Engl J Med*. 2010;362:886–95.
6. Genders TS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. *Eur Heart J*. 2011;32:1316–30.
7. Diamond GA, Kaul S. Low diagnostic yield of elective coronary angiography. *N Engl J Med*. 2010;363:93, author reply 4–5.
8. Cheng YV, Berman DS, Rozanski A, et al. Performance of the traditional age, sex, and angina typicality-based approach for estimating pretest probability of angiographically significant coronary artery disease in patients undergoing coronary computed tomographic angiography: results from the Multinational Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry (CONFIRM). *Circulation*. 2011;124:2423–32.
9. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med*. 1979;300:1350–8.
10. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. *Ann Intern Med*. 1993;118:81–90.
11. Douglas PS, Patel MR, Bailey SR, et al. Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. *J Am Coll Cardiol*. 2011;58:801–9.
12. Cole JH, Chunn VM, Morrow JA, et al. Cost implications of initial computed tomography angiography as opposed to catheterization in patients with mildly abnormal or equivocal myocardial perfusion scans. *J Cardiovasc Comput Tomogr*. 2007;1:21–6.
13. Abidov A, Gallagher MJ, Chinnaiyan KM, et al. Clinical effectiveness of coronary computed tomographic angiography in the triage of patients to cardiac catheterization and revascularization after inconclusive stress testing: results of a 2-year prospective trial. *J Nucl Cardiol*. 2009;16:701–13.
14. Chow BJ, Abraham A, Wells GA, et al. Diagnostic accuracy and impact of computed tomographic coronary angiography on utilization of invasive coronary angiography. *Circ Cardiovasc Imaging*. 2009;2:16–23.
15. Lesser JR, Flygenring B, Knickelbine T, et al. Clinical utility of coronary CT angiography: coronary stenosis detection and prognosis in ambulatory patients. *Catheter Cardiovasc Interv*. 2007;69:64–72.
16. Halpern EJ, Fischman D, Savage MP, et al. Decision analytic model for evaluation of suspected coronary disease with stress testing and coronary CT angiography. *Acad Radiol*. 2010;17:577–86.
17. Halpern EJ, Savage MP, Fischman DL, et al. Cost-effectiveness of coronary CT angiography in evaluation of patients without symptoms who have positive stress test results. *AJR Am J Roentgenol*. 2010;194:1257–62.
18. Weustink AC, Mollet NR, Neefjes LA, et al. Diagnostic accuracy and clinical utility of noninvasive testing for coronary artery disease. *Ann Intern Med*. 2010;152:630–9.
19. Chinnaiyan KM, Raff GL, Goraya T, et al. Coronary computed tomography angiography after stress testing: results from a multicenter, statewide registry, ACIC (Advanced Cardiovascular Imaging Consortium). *J Am Coll Cardiol*. 2012;59:688–95.
20. Skinner JS, Smeeth L, Kendall JM, et al. NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. *Heart*. 2010;96:974–8.
21. Shreibati JB, Baker LC, Hlatky MA. Association of coronary CT angiography or stress testing with subsequent utilization and spending among Medicare beneficiaries. *JAMA*. 2011;306:2128–36.
22. National Heart, Lung, and Blood Institute (NHLBI). PROspective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE). In: ClinicalTrials.gov NLM Identifier: NCT01174550 [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. Available from: <http://www.clinicaltrials.gov/ct2/show/NCT01174550?term=promise&rank=7> [accessed 03.01.12].
23. Erasmus Medical Center. Computed Tomography Versus Exercise Testing in Suspected Coronary Artery Disease (CRESCENT). In: ClinicalTrials.gov [Internet]. Identifier: NCT01393028. Bethesda (MD): National Library of Medicine (US). 2000. Available from: <http://www.clinicaltrials.gov/ct2/show/NCT01393028?term=crescent&rank=1NLM> [accessed 03.01.12].